Amundi Holds $1.23 Billion in Gilead Shares as Some Funds Add More
The institutional investor owned 9,772,438 Gilead Sciences shares after selling 766,673 during the quarter, while HighTower Advisors increased its stake and Amundi’s holdings were valued at $1.23 billion. The summary also notes new HIV and oncology approvals, a $0.82 quarterly dividend, and quarterly earnings of -$6.75 per share that beat consensus by $0.50.